作者
Livia Casciola-Rosen, David R Thiemann, Felipe Andrade, Maria I Trejo-Zambrano, Elissa K Leonard, Jamie B Spangler, Nicole E Skinner, Justin Bailey, Srinivasan Yegnasubramanian, Rulin Wang, Ajay M Vaghasia, Anuj Gupta, Andrea L Cox, Stuart C Ray, Raleigh M Linville, Zhaobin Guo, Peter C Searson, Carolyn E Machamer, Stephen Desiderio, Lauren M Sauer, Oliver Laeyendecker, Brian T Garibaldi, Li Gao, Mahendra Damarla, Paul M Hassoun, Jody E Hooper, Christopher A Mecoli, Lisa Christopher-Stine, Laura Gutierrez-Alamillo, Qingyuan Yang, David Hines, William A Clarke, Richard E Rothman, Andrew Pekosz, Katherine ZJ Fenstermacher, Zitong Wang, Scott L Zeger, Antony Rosen
发表日期
2022/5/5
期刊
JCI insight
卷号
7
期号
9
出版商
American Society for Clinical Investigation
简介
Background
Some clinical features of severe COVID-19 represent blood vessel damage induced by activation of host immune responses initiated by the coronavirus SARS-CoV-2. We hypothesized autoantibodies against angiotensin-converting enzyme 2 (ACE2), the SARS-CoV-2 receptor expressed on vascular endothelium, are generated during COVID-19 and are of mechanistic importance.
Methods
In an opportunity sample of 118 COVID-19 inpatients, autoantibodies recognizing ACE2 were detected by ELISA. Binding properties of anti-ACE2 IgM were analyzed via biolayer interferometry. Effects of anti-ACE2 IgM on complement activation and endothelial function were demonstrated in a tissue-engineered pulmonary microvessel model.
Results
Anti-ACE2 IgM (not IgG) autoantibodies were associated with severe COVID-19 and found in 18/66 (27.2%) patients with severe disease compared with 2/52 (3.8%) of …
学术搜索中的文章
L Casciola-Rosen, DR Thiemann, F Andrade… - JCI insight, 2022